Gilead Sciences — how they publish

10 posts · curated by ViralLoop

80 posts from @GileadSciences, Nov 2025 to Aug 2026: a typical post earns 9 likes. That is more than 61% of the 275 other S&P 500 companies we hold content for. About 1 in 4 of their posts opens with a number.

Gilead Sciences@GileadSciences

Cue the highlights: standout moments, innovative science and meaningful progress across Gilead and @KitePharma in 2025. From major global achievements to everyday team accomplishments, this work helped define who we are, where we’re going and how far we still want to go.

Opens with an observation

Gilead Sciences@GileadSciences

#GileadNews: The U.S. FDA approves first and only single-tablet regimen for the treatment of HIV in adults who are virologically suppressed, including those on complex multi-tablet regimens. Learn more: t.co

Opens with an observation

Gilead Sciences@GileadSciences

#GileadNews: The U.S. FDA has accepted our filing for our investigational once-weekly oral option for the prevention of HIV as pre-exposure prophylaxis (PrEP). If approved, this formulation could be the first once-weekly oral PrEP option. Read more: t.co

Opens with an observation

Gilead Sciences@GileadSciences

Every patient’s journey is unique, and their powerful stories inspire our commitment to advancing cancer care with science that meets people where they are. This #WorldCancerDay, we remain committed to science that changes what cancer treatment can mean for those living with it.

Opens with an observation

Gilead Sciences@GileadSciences

We create possibilities when great minds, cutting-edge technology and bold vision converge. Our investments in AI, biotech partnerships and next-gen facilities are building tomorrow's medicine blueprint right here in America.  t.co

Opens with an observation

Gilead Sciences@GileadSciences

In an era of rapid scientific advancement and ongoing global health challenges, we’re taking a forward-looking approach to innovation – guided by our long-term plan to advance 10 potential transformative therapies by 2030. Read more in @endpts. #JPM2026 t.co

Opens with an observation

Gilead Sciences@GileadSciences

#GileadNews: Today, in collaboration with @Merck, we announced positive topline results from a Phase 3 study evaluating an investigational long-acting oral HIV treatment. Read the full press release here: t.co

Opens with an observation

Gilead Sciences@GileadSciences

#GileadNews: We received a #CHMP positive opinion for our combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer. If approved, patients with PD-(L)1 positive mTNBC will have a new treatment option in Europe. t.co

Opens with an observation

Gilead Sciences@GileadSciences

#GileadNews: At #AIDS2026, in collaboration with @Merck, we’re presenting new data from our Phase 3 trials evaluating an investigational long-acting oral treatment for adults with virologically suppressed HIV. Read the full press release here: t.co

Opens with a number

Gilead Sciences@GileadSciences

#GileadNews: U.S. FDA approves our treatment for first-line metastatic triple-negative breast cancer, marking a new backbone therapy for people who previously had few options. Read more on this much-needed treatment option for the mTNBC community: t.co

Opens with an observation